Iovance Biotherapeutics to Host Virtual Roundtable with Key Opinion Leaders to Discuss Melanoma Treatment Landscape
20 juin 2023 07h01 HE
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor...
Iovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced Melanoma
15 juin 2023 07h01 HE
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., June 15, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor...
Iovance Biotherapeutics to Present at Jefferies Global Healthcare Conference
09 juin 2023 07h01 HE
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma
26 mai 2023 17h30 HE
|
Iovance Biotherapeutics, Inc.
Priority Review Granted withPrescription Drug User Fee Act (PDUFA) Action Date of November 25, 2023 First Potential Approval of an Individualized, One-Time Cell Therapy for Patients with Advanced...
Iovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
09 mai 2023 16h01 HE
|
Iovance Biotherapeutics, Inc.
First Biologics License Application (BLA) Submission Completed in March 2023 Commercial Readiness Activities on track to Support Potential Commercial Launch of Lifileucel in 2023 SAN CARLOS,...
Iovance Biotherapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, May 9, 2023
02 mai 2023 16h01 HE
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will...
Iovance Biotherapeutics to Present at Upcoming Conferences
24 avr. 2023 07h01 HE
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
24 mars 2023 16h01 HE
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics to Present at Upcoming Conferences
01 mars 2023 08h03 HE
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
28 févr. 2023 16h01 HE
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor...